you. Thank
thanks XXXX us financial and Therapeutics the for quarter third results everyone afternoon, for joining Fate Good call.
Shortly after X:XX p.m.
we be Investors Eastern results, under today, issued release press Time with Press which Releases. can of found section the on our website a these
shortly Form Investors filed section website Financial and addition, of XXXX our ended XX, found Information. for our XX-Q In can quarter be the September was thereafter the on under
facts, statements they made reflect market that statements, of the law, XX, date placed forward-looking should Except as to forward-looking future facts as Fate except begin, September Litigation statements be I forward-looking release included obligation only to circumstances. issued that for such factors Securities speak statements the those Reform the risks ended underlying forward-looking would press management in involve and required information, actual or quarter statement Therapeutics XX-Q Harbor company's statements Private responses XXXX. circumstances made to forward-looking the the risk XXXX of statements. are these earnings update that close the materially of Safe provisions our by and this historical and not we statements as events these the Form filed by Before statements Please see from disclaimer conference on today. in can forward-looking remind may of Undue for with on Act on the change. uncertainties disclaims under SEC like results questions the the reliance everyone are as as which was of These after today to any cause to differ well call
data the Dr. Wayne several we over Dr. Valamehr, Clinical cell NK our off Research Senior a these from today's our the Development preclinical in shelf on our with in lymphomas. Dulac, T-cell Autologous our President and and cell remarkable Chief clinical Chu, results immunotherapy months share will Hematology with mid-November, certain for of B our the and Chief Bob our me past clinical of in therapies connection programs of refractory with Officer; targeting programs franchise. Beginning discuss Society to B for meeting iPSC of highlight Officer. cell annual American and Financial derived CAR CDXX have malignancy progress mid-December. Joining Today, cancer call our annual development; with and Ed Vice meeting patients society relapsed are plans delivered
shelf a can cell remains to bring that more there outcomes However, significant based to off the cancer develop transformative immunotherapies patients. need
months, clinical FTXXX several NK cell clinical of past the in candidates, our progress programs Over patient we investigation including product FTXXX populations. expanding shelf the IPS significant off have broader these made derived to and advancing
clinical the very We with continue data. to be early pleased
antigen through designed of requiring antigen escape. IPSC shelf our objective receptor we a with addressing outpatient CAR second in monotherapy without off supports FTXXX FTXXX hold cutoff million believe as from safety X those data observed the targeting with class in may and in have clinical as XX of settings. receptor in well its drive both combination differentiated care of and seven while antibodies. cell substantially that therapies Fc August, We with affinity and we combination tumor derived data achieved assessed XX antigens, rituximab, setting dose combination a cohorts through to CDXX may a FTXXX multi escalating high studies T-cell single NK dose hospitalization, our with with potential comparable community its relapsed non-cleavable In announced an of XXXX, FTXXX In is the targeted is used only our of being potential shown and respectively. CDXX in B dose enable Phase approach have study including refractory best lymphoma, as and third antigen also XXX that maintaining targeting administration product line regimens cells earlier X that tumor target in heterogeneity, patients standard of FTXXX response million B response treated a cell Phase in that and profile cells are CAR but candidate interim multiple not of rates that autologous cell the treatment achieved complete to to XX June where response, date XX the patients achieved as chimeric
safety adverse disease. with to cytokine that a T-cell CDXX single differentiated commonly a patients low host had observed of effector graft therapy. complete syndrome, been FTXXX FTXXX of was of no With rituximab. and reported showed events CAR two reported dose with events Treatment and or two therapy, whom XX T-cell grade previously achieved with autologous cell a well in associated only profile of these of neurotoxicity CAR versus four with with tolerated treated release Importantly, adverse immune response combination
be dose third in for XXX is fourth tumor December through enrolled our respectively. featured million We all approximately and Phase third presentation presentation we response response rituximab. Monday, in announced today, data monotherapy Earlier cohorts million treated dose at the patients cells of updated and in cells oral combination have an duration now FTXXX cells, to million of clinical XX with XXX that XX XX. single of The study expected second, XXX as from Total X and cells will single million the patients cohort safety, ASH cover on and
cohort further December we to response data investor and where in tumor safety an plan dose present In expect for treated event addition, patients those of fourth the presentation, single Tuesday, we to to ASH on million cells. supplement the XX, XXX hold
the that observed over no that single well treatment that continue shelf to and best-in-class off patients. one limiting cycles, believe dose deliver tolerated dose for multiple To treatment that having FTXXX with end, will toxicities. is of confer a We of doses potential a was to significant the cell multiple such therapy paradigm advantage outcomes cycle
increased one at day per FTXXX and now of frequency treatment FTXXX million enrollment XX cells dosing have and dose cycle, We administered dose, of day two on initiate the a with XXX XXX two clinical receive with the benefit showing potential two treatment dose eligible to dose first second dose a escalate to treatment cycle. following the per million cells are dose. to cycle, Patients
malignancies patient based include we Phase on to FTXXX refractory clinical pleased we cells per of refractory the our Additionally, investigation relapsed X patients that of lymphoma, study, XX dose. with the enrollment broadened the interim of other of announce treatment obinutuzumab have CLL at initiated clinical for have data million B-cell I'm in with our ongoing have treated observed positive to first with we and FTXXX relapsed combination B-cell in treatment FTXXX have and
the grade potential and in FTXXX as profile response maintained responses. in without FTXXX clinical FTXXX rituximab on third safety the X.X graft-versus-host interim of from July is has therapeutic per indicating the the XXX FTXXX Turning observed. any two drive we and achieved dose XX second treatment therapies. three second reported. up serious August, And that the of an events, was of XX XX multi syndrome, cohorts patients combination The on with No cells date to and B-cell X In that effector grade for of our intervention, dose of between from events that million were study per adverse lymphoma. of were based further FTXXX of of events objective months, announced complete disease going observed XX of response, cutoff data of no or or favorable, release differentiated cells cell also treatments follow relapsed patients million Eight durable with cycle. immune X T-cell the refractory of neurotoxicity Five adverse related FTXXX. FTXXX patients X.X escalating related or of day associated response greater their XXXX up and six cytokine positive dose, data the achieved including Phase dose,
be We Phase have million dose clinical duration FTXXX enrolled our the cohort the that XXX all our dose stage of XX patients X announced multi-dose study, we cohorts. third dose. second, fourth response in at study from XX. on featured is December cover expected a to Earlier ASH poster at of fourth The seven data presentation the patients of treated per Phase and safety, cells now multi FTXXX for having and updated response in completed will X presentation today, Monday tumor escalation
CDXX lymphomas naive CAR Number three with CDXX a two, therapy. further the lymphoma following disease that We T-cell therapy three large naive in into CAR third disease to refractory to of autologous lymphoma in are CDXX diffuse patients CAR cohorts XXX plan line third are addition, B-cell the to opportunity. has intending Tuesday the T-cell with therapy. autologous assess activity whose and activity need one on In B-cell progressed are enroll assessing to segment has significant follicular growing we ASH may updated believe XX. patients December per escalation, to at cells FTXXX we relapsed further patients unmet dose addresses CAR presentation dose disease of to in clinical million fast investor following our autologous development a market initiated progressed with whose expansion supplement autologous FTXXX data line market potential specific dose FTXXX completed event T-cell patients T-cell therapy have including and CDXX now offer that and Having patients at clinical
also its be that chemotherapy may targeted earlier settings. profile setting, line favorable In regimens given its to-date, rituximab observed in Cy/Flu administered with of combine standard-of-care, to in have FTXXX conditioning explore community outpatient with dose initiated combination expansion addition, to used bendamustine because the without and in and are potential FTXXX we CDXX safety and
Importantly, serve to sites in the patients these we community include expansion in cohorts, four dose that intend setting.
in multiple Phase the pleased targeted of our daratumumab. antibody FTXXX escalating that combination with CDXX myeloma disease I'm first patient announce we in have to our to treated monoclonal study dose franchise, X Turning
backbone with product engineered builds FTXXX innate and immunity. of functional our Our is FTXXX optimize candidate to components off three
designed to oxidative of assess function. the and enhanced showed to preclinical attributable with receptor novel IL-XX non fitness, FTXXX novel In relapsed fusion and combination refractory the three functional cells. CDXX once receptor doses, study activation stress weekly fusion killing, FTXXX was CDXX treatment a program FC the of published and increase in blood an the persistence cellular the Reviewed protein high Peer peripheral addition for recently a NK metabolic Cell, FTXXX compared effects Stem of In Cell its resistance IL-XX we were in X knock-out, that daratumumab dependent cleavable which induces of Journal superior Phase receptor, deletion and enhanced FTXXX NK shown and incorporates of myeloma. serial that anti-tumor The exhibits cell expression cytotoxicity gene. The effector improve to CDXX is biological affinity studies activity to to to antibody multiple
Similar dose. FTXXX, our per The first at cells patient we our further FTXXX. lymphoma, have treated was approach to are developing create in candidate we product and to FTXXX million XXX where modified FTXXX
multiple Our candidate off-the-shelf product CDXX designed its NK targeted BCMA IPS receptor and CAR avidity target derived non-cleavable its through high affinity antigens, both chimeric high receptor. to antigen FC cell
assess which cohort, million CDXX BCMA dose enrollment to of We dose and at Phase hold the antigens, best-in-class well X FTXXX XXX as in treatment will believe have monotherapy, begin dosing both escalating that in and Patient our treatment regimens targeting for FTXXX daratumumab, single multiple study as potential approach as dose dose monotherapy we initiated of the an as in both combination with of a dose treatment myeloma. enables cells. may with of multi single
about we franchise, to AML. the cell of disease continue foundational to the AML our potential role treatment excited in of a NK therapies IPS be with patients to play derived Turning
NK programs, complete We the marrow. are tolerated of have and can FTXXX and our are cells initial leukemic clinical that from encouraged blasts from responses bone induce well X objective derived with by which IPS indicated Phase data FTXXX our clearance
and setting. achieved, IPS outpatient cells clinical off-the-shelf these NK Importantly, outcomes derived with administer were the in
has additional the three dose accordingly. strides rate made months, in we opening sites, of past study significant escalating of have accelerated FTXXX Phase enrollment X our clinical Over at our and
also XXX AML. recognize cells No patients million toxicities with patients with investigator of respectively. the in and dose AML affinity in We the dose, continues CDXX kill expressing now XX and non-cleavable enrollment cells relapsed be cellular an CDXX candidates' well dose limiting product first been We've receptor high therapeutic clinical per in and dose initiated Phase proprietary exploit A relapsed combination leukemic to FTXXX antibody cytotoxicity. million multi reported, daratumumab X cohorts of designed enrolled in through strategy second dependent refractory per approximately have to trial and knock-out CDXX to with with FTXXX, blasts XXX tolerated. bind and commenced have treatment refractory
have not enrolled study FTXXX third refractory dose million XXX The patients X in also well of of our multi dose was per FTXXX treatment cells the dose. and We completed dose seven established, escalation having relapsed cohort the FTXXX stage tolerated tolerated. Phase AML, of was maximum with in
to generate FTXXX, additional and including look update of of FTXXX programs. to safety on we're in durability dose response, we AML our both will programs the response as an antileukemic data relapse We provide of with duration FTXXX refractory and compare so fully activity escalation able
will targeting presented Turning IND franchise. will tumor NK preclinical MICA the cell is is to be and presentation. binding that novel specifically shedding MICA/MICB. CAR Saturday to where Alpha the expression product and oral conference FTXXX antigens, X CAR NK tumor of cell solid IPS an domain on data our escape looking of our the highlight FTXXX be candidate designed overcome engineered multiplexed will mediated of domain And next for the off-the-shelf stress We're mechanisms incorporates by assist forward derived FTXXX, week, featured pan MHC loss novel tumor by program MICB. Citi to X which in class associated a XX. November FTXXX enabling of
treatment application We FTXXX in exploit the fourth monoclonal for antigen tumors, submit of an of in multi XXXX expect to quarter with the therapy antibody IND advanced including to targeting. combination solid for
product we In investor and for multiplexed a to addition, XX, event, of IPS emerging engineered highlight tumors. to our solid on pipeline November virtual Monday, XX-minute derived T-cell off-the-shelf NK intend host candidates
multi tumor the discuss The mechanisms integration tumors, functionality multiplex During to the action platform we features to candidates product IND that solid unique product next intend plan in candidates of with the our associated have as multiplexed during our single patients for we that enrollment in our solid tumors, preclinical antibody plan antigens, therapy. tumors EGFR, tumor checkpoint IPSC attacking from engineered And candidates to monoclonal into applications currently checkpoint FTXXX study clinical therapy, resistance checkpoint including X HERX for also we product and we and inhibitor have to in which following; assessing initiated PDL-X. patients generation with targeting the for we event progressed in are with FTXXX that our that solid Phase in and combination selection where proprietary therapy, and XX combination investor seek solid our submit to months. armed of well disclose failed or first target inhibitor candidates new tumor and data engineering those exploit as innovative or inhibitor of
cancer of Our at and checkpoint per in therapy. classical Phase that enrolled cell X has approximately patients lung progressed heavily XX with study dose, have pretreated lymphoma PDL-X failed patients XXX or inhibitor million FTXXX includes or PD-X Hodgkin non-small cells dose expansion
would XXX from FTXXX pretreated of patients includes million to cells XX study highlight PD-X PDL-X enrolled third or escalation, XX progressed have that dose X our cells Phase the turn to heavily checkpoint melanoma dose, per now patients dose primarily financial to and failed call inhibitor to Our results. has approximately ranging over in X per Ed million stage like with quarter therapy. I
